Novo led a $60m Series C round in Exscientia, a drug discovery company, with existing investors – Evotec, Bristol Myers Squibb, and GT Healthcare Capital. The new capital will be used to boldly expand Exscientia’s existing portfolio and pipeline, by launching new projects, progressing advanced projects to the clinic, and expanding AI biology as part of Exscientia’s full-stack capabilities. In addition, the company plans to accelerate its international expansion, including the build-out of its presence in the USA.